The complete workshop program is available here.
This 3-day HESI workshop will demonstrate how science-based safety assessment is advanced through cooperative partnerships among government, industry, and academia. Each session will feature an overview of HESI’s activities on the topic, presentations from international experts, and panel discussions which include government, industry, and academic scientists from the US and Europe.
Internationally recognized experts in toxicology and risk assessment will participate as speakers, moderators, and panelists at the workshop. Some of the confirmed speakers include:
The meeting is open to participants from industry, academia, and government from Europe and abroad. The workshop programs will be of interest across sectors, and diverse perspectives will be offered. HESI encourages participation from both those familiar or affiliated with the HESI organization and those who would like to learn more about HESI programs.
With recent advances in analytical detection techniques for DNA adducts comes the need to address recurring questions about the mechanistic and toxicological relevance of low-concentration measured adducts. Despite the abundance of research in this field, the diversity of opinions as to the role of DNA adducts in cellular processing, repair mechanisms, and mutagenesis (and vice versa) suggests the need for a mechanism to reach scientific consensus. Concurrent with the increasingly widespread collection of DNA adduct measurements as human biomarker data, the scientific community is also currently debating the relevance of these data for risk assessment. This special session will address activities undertaken by HESI to further public discussion and consensus on the use of DNA adducts for risk assessment.
Program
Welcome and Introduction
Ms. Syril Pettit or Dr. Michael Holsapple (HESI) (confirmed)
Speakers
Chair: Dr. Bennett van Houten (US National Institute of Environmental Health Sciences)
Available Tools for Measuring DNA Adducts
Dr. David Shuker (Open University, UK)
DNA Adducts in Risk Assessment
Dr. Elizabeth Martin (AstraZeneca)
US Regulatory Perspective
Dr. Julian Preston (US Environmental Protection Agency National Health and Environmental Effects Research Laboratory)
European Regulatory Perspective
Dr. Peter Kasper (Federal Institute for Drugs and Medical Devices, Germany)
Panel Discussion
Moderator: Dr. Bobby Kroes (Utrecht University) (confirmed)
Rapporteur: Dr. Jay Goodman (Michigan State University) (confirmed)
Panelists
Dr. Jean Cadet (French Atomic Energy Commission) (confirmed)
Prof. Dr. Helmut Greim (University of Munich) (confirmed)
Dr. Ben Van Houten (US National Institute of Environmental Health Sciences) (confirmed)
Dr. Veronique Thybaud (sanofi-aventis) (confirmed)
Dr. Robert Baan (International Agency for Research on Cancer) (confirmed)
From 1989 (the year that HESI was founded) until 1994, HESI hosted a series of five Mouse Liver Tumor Workshops, each of which were co-sponsored with the US Environmental Protection Agency. During the fifth and final workshop in this series, participants began to consider a key question: “What constitutes a definition of robust evidence for a mode-of-action that would be sufficient to override a default regulatory posture?” This early HESI work provided a critical foundation for the development of a mode-of-action (MoA) framework. The first step in this framework is to establish the key biochemical and cellular events, temporal occurrence, and dose-response concordance relationships for the MoA in animals.
The next step is to assess the biological plausibility of the key events in humans. The final step is to consider kinetic and dynamic factors to establish the relevance of the MoA in humans. This MoA framework has been previously applied to rodent liver tumors associated with exposure to peroxisome proliferators mediated through the alpha receptor (Klaunig et al., 2003, Crit. Rev. Toxicol., 33:655-780). In May 2004, HESI co-organized a workshop to apply this framework approach to several additional MoAs for rodent liver tumor development including cytotoxicity, P-450 induction, hormone-mediated events, porphyrogenicity, and metal overload. This workshop will focus on the outcomes and recommendations emerging from the May 2004 HESI workshop on the human relevance of rodent liver tumors.
Program
Welcome and Introduction:
Dr. Michael Holsapple (HESI)
Speakers
Chair: Dr. Lewis Smith (Syngenta Ltd.)
Overview on Multi-stage Hepatocarcinogenicity
Dr. Rolf Schulte-Hermann (Medical University of Vienna)
Introduction to the Mode-of-action Framework Approach
Dr. James Klaunig (Indiana University)
Peroxisome Proliferation
Dr. Ruth Roberts (AstraZeneca)
Cytotoxicity
Dr. Sam Cohen (University of Nebraska Medical Center)
P450/Phenobarbital-like
Prof. Alan Boobis (Imperial College London)
Estrogenicity
Dr. Timothy Pastoor (Syngenta CropScience)
US Government Perspective
Dr. Vicki Dellarco (US Environmental Protection Agency Office of Pesticide Programs)
Dr. David Jacobson-Kram (US Food and Drug Administration Center for Drug Evaluation and Research)
European Government Perspective
Dr. Jan Willem van der Laan (National Istitute of Public Health and the Environment, Germany) (confirmed)
Panel Discussion
Moderator: Dr. Ernie Harpur (sanofi-synthelabo) (confirmed)
Rapporteur: Dr. Andy Smith (MRC/University of Leicester)
Panelists
Dr. Beatriz Silva Lima (National Institute for Pharmacy and Medicines and University of Lisboa, Portugal)
Dr. Robert Baan (International Agency for Research on Cancer)
Dr. Gerd Bode (Atlanta Pharma AG)
Dr. Klaus Olejniczak (Federal Institute for Risk Assessment, Germany)
Dr. Bette Meek (Health Canada)
Dr. Jay Goodman (Michigan State University)
Dr. Dominique Masset (European Agency for the Evaluation of Medicinal Products, AFSSAPS, France)
In 2004, the HESI Technical Committee on Agricultural Chemical Safety Assessment (ACSA), an international group of government, academic, and industry scientists, completed a multi-year project to develop an improved testing strategy for assessing the safety of crop protection chemicals. The tiered testing approach integrates metabolic and kinetic data into the safety assessment process; takes an integrated approach to evaluating life stage effects, systemic toxicity, and kinetics; and is guided by human exposure predictions. During this workshop, leaders of the ACSA Technical Committee described the tiered testing strategy and its underlying scientific basis, logic, and flexibility. In addition, speakers quantified the reduction in the number of experimental animals required to perform a sound assessment using this approach and summarized government reception to the proposal to date.
Program
Welcome and Introduction
Nancy G. Doerrer, MS (HESI)
Speakers
Chair: Dr. Neil Carmichael (Bayer CropScience) (Presentation)
ADME
Dr. Hugh Barton (US Environmental Protection Agency National Center for Computational Toxicology) (Presentation)
Systemic Toxicity
Dr. John Doe (Syngenta CTL) (Presentation)
Life Stage
Ms. Lorraine Irvine (toXcel International) (Presentation)
Integration of Approaches
Dr. Neil Carmichael (Bayer CropScience) (Presentation)
US Government Perspective
Dr. Vicki Dellarco (US Environmental Protection Agency Office of Pesticide Programs) (Presentation)
"OECD Perspective"
Dr. Drew Wagner (Organisation for Economic Cooperation and Development) (Presentation)
Panel Discussion
Moderator: Prof. Alan Boobis (Imperial College London)
Rapporteur: Dr. Angelo Moretto (University of Padua)
Panelists
Dr. Vicki Dellarco (US Environmental Protection Agency Office of Pesticide Programs)
European Food Safety Authority Representative (invited)
Dr. Claire Franklin (University of Ottawa; formerly with Health Canada)
Dr. James Klaunig (Indiana University School of Medicine)
Dr. Roland Solecki (Federal Institute for Risk Assessment, Berlin)
Dr. Drew Wagner (Organisation for Economic Cooperation and Development)
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.